OR WAIT null SECS
Discussing Significance of Delayed Response to Lebrikizumab in Initial Nonresponders
This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.
An interview was conducted following the release of new data at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference on the impact of of lebrikizumab (Ebglyss) on atopic dermatitis in adult and adolescent patients with skin of color. The HCPLive editorial team spoke with Andrew Alexis, MD, MPH, ADmirable investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine, about the new phase 3b findings on lebrikizumab in atopic dermatitis for patients with skin of color.
The study’s main efficacy measure had been 75% or greater improvement in patients’ Eczema Area and Severity Index (EASI) scores. EASI-75 response rates were noted by the investigators as having increased through Week 24, particularly in participants with skin phototype VI. Alexis highlighted that in a cohort of subjects who were considered non-responders at Week 16, when these patients remained on treatment with lebrikizumab every 2 weeks, almost half of them went on to be responders at the 24-week mark.
Given this substantial proportion of initial nonresponders achievement of response with continued Q2W dosing, Alexis highlighted what might this suggest about persistence with therapy when treating patients who do not respond to lebrikizumab treatment early.
Alexis has reported advisory/consulting fees from companies including Lilly.
References
Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: final 24-wWeek results from the phase 3b, open-label ADmirable study. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Accessed June 18, 2025. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and.
